Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
TL1A Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | O95150 |
| Other Accession | AAM77366, 21745392 |
| Reactivity | Human, Mouse, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Calculated MW | Predicted: 28 kDa Observed: 26 kDa |
| Application Notes | TL1A antibody can be used for detection of TL1A by Western blot at 0.5 to 2 µg/mL. |
| Gene ID | 9966 |
|---|---|
| Other Names | TL1A Antibody: TL1, TL1A, VEGI, VEGI192A, TL1, Tumor necrosis factor ligand superfamily member 15, TNF ligand-related molecule 1, tumor necrosis factor (ligand) superfamily, member 15 |
| Target/Specificity | TNFSF15; This polyclonal antibody will not cross-react with TL1. |
| Reconstitution & Storage | TL1A antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| Precautions | TL1A Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | TNFSF15 |
|---|---|
| Synonyms | TL1, VEGI |
| Function | Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis. |
| Cellular Location | Membrane; Single-pass type II membrane protein |
| Tissue Location | Specifically expressed in endothelial cells. Detected in monocytes, placenta, lung, liver, kidney, skeletal muscle, pancreas, spleen, prostate, small intestine and colon |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
TL1A Antibody: Members in the TNF and its receptor superfamilies regulate immune responses and induce apoptosis. DR3 (also termed Wsl-1, Apo-3, TRAMP, and LARD) is preferentially expressed by T lymphocytes and upregulated during T cell activation. The ligand for DR3 was recently identified and designated TL1A. TL1A also binds decoy receptor DcR3/TR6, which is expressed in several lung and colon carcinomas and in some normal tissues. TL1A induces apoptosis and NF-κB activation in DR3 expressing cells, which is antagonized by DcR3. TL1A is upregulated by proinflammatory cytokines TNF and IL-1. TL1A is a longer variant of TL1 (also called VEGI).
References
Chinnayan AM, O’Rourke K, Yu GL, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996; 274:990-2.
Kitson J, Raven T, Jiang YP, et al. A death-domain-containing receptor that mediates apoptosis. Nature 1996; 384:372-5.
Screaton GR, Xu XN, Olsen AL, et al. LARD: a new lymphoid-specific death domain containing receptor regulated by pre-mRNA splicing. Proc. Natl. Acad. Sci. USA 1997; 94:4615-9.
Bodmer JL, Burns K, Schneider P. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas (Apo-1/CD95). Immunity 1997; 6:79-88.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
